Heartcore Capital

Teitur Trophics is a biotech company established in 2020 and based in Aarhus, Denmark. The company specializes in the development of circular peptides aimed at addressing neurodegenerative diseases. Its research focuses on small peptides that interact with receptors central to neural function. By gaining insights into the biology of these receptors, Teitur Trophics aims to modulate key mechanisms in neural function, which may facilitate the creation of innovative treatments. These treatments are designed to be administered through daily injections, with the potential to prevent the onset of neurodegenerative conditions.

Ascelia Pharma is a biotechnology company based in Malmö, Sweden, dedicated to the development of oncology treatments, particularly for orphan diseases. The company specializes in creating novel drugs that target unmet medical needs and possess clear pathways for development and commercialization. Currently, Ascelia Pharma is advancing two drug candidates, Orviglance and Oncoral, which are in clinical development stages. The company's focus on rare cancers highlights its commitment to addressing significant gaps in treatment options within the oncology sector.

Tink is a cloud-based open banking platform that provides the infrastructure and value-adding data products that are enabling the future of financial services. Tink offers products such as account aggregation, payment initiation, data enrichment, and personal finance management that can be used to develop standalone services or be integrated into existing banking applications. Its partners include ABN AMRO, BNP Paribas Fortis, Nordea, Klarna, and SEB. Tink was founded in 2012 and is based in Stockholm, Sweden.

Traplight creates ultra approachable and deep F2P games. From the first seconds their games offer you fun, effortless gameplay and a deep, empowering progression. They focus on creating entertainment that lasts for years and is always fresh. Players are the ones they create their games for, not us. This drives us to make fun, empowering and coherent gaming experiences that their players truly want. Founded in 2010 and based in Tampere, Finland, Traplight currently has a 28 strong team working on several games. Traplight’s team and vision have been backed up by renowned game investors such as Initial Capital, Korea Investment Partners, Sunstone Capital and Finnvera Venture Capital. Traplight’s Big Bang Racing was chosen as Best of 2016 in AppStore, and currently the company is preparing to soft launch their next big hit soon.

Tink is a cloud-based open banking platform that provides the infrastructure and value-adding data products that are enabling the future of financial services. Tink offers products such as account aggregation, payment initiation, data enrichment, and personal finance management that can be used to develop standalone services or be integrated into existing banking applications. Its partners include ABN AMRO, BNP Paribas Fortis, Nordea, Klarna, and SEB. Tink was founded in 2012 and is based in Stockholm, Sweden.

Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company specializes in creating novel therapeutic drugs that address urological and endocrinological diseases by focusing on tissue-specific regulation of sex hormone effects. Among its key developments is Fispemifene, a selective estrogen receptor modulator aimed at treating low testosterone symptoms in men. Forendo Pharma also works on a 17HSD1-inhibitor targeting endometriosis, thereby addressing broader gynecological conditions. Through its innovative approach, the company seeks to enhance treatment options for both men's and women's health, particularly in areas that have previously been underserved.

Tink is a cloud-based open banking platform that provides the infrastructure and value-adding data products that are enabling the future of financial services. Tink offers products such as account aggregation, payment initiation, data enrichment, and personal finance management that can be used to develop standalone services or be integrated into existing banking applications. Its partners include ABN AMRO, BNP Paribas Fortis, Nordea, Klarna, and SEB. Tink was founded in 2012 and is based in Stockholm, Sweden.

Templafy ApS specializes in template and document management solutions designed to enhance business document creation across various industries, including banking, finance, consulting, education, insurance, consumer, and legal sectors. Founded in 2013 and headquartered in Copenhagen, Denmark, Templafy offers a platform that integrates seamlessly with existing software to automate document generation, ensuring brand compliance and improving productivity. Its services include dynamic personalization, document automation, content accessibility, and template governance, enabling organizations to create compliant, high-performing documents efficiently. The company supports millions of users globally, serving over 800 enterprise customers, including notable names like KPMG and IKEA. Templafy operates in multiple countries, including the United States, Germany, the Netherlands, the United Kingdom, Singapore, Hong Kong, Australia, New Zealand, and Spain.

Grandhood is an investment management company based in Copenhagen, Denmark, founded in 2016. It specializes in providing innovative retirement planning and pension services through a digital self-service platform. The company aims to modernize the workplace pension industry by offering a user-friendly application that enables employers to facilitate access to pensions for their employees. In addition to retirement solutions, Grandhood's offerings include voluntary health insurance and insurance coverage for reduced working capacity, death, and certain critical illnesses. The company is committed to delivering low-cost, efficient advisory services, with a focus on rapid customer support and ongoing product innovation to meet the evolving needs of its clients.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Tink is a cloud-based open banking platform that provides the infrastructure and value-adding data products that are enabling the future of financial services. Tink offers products such as account aggregation, payment initiation, data enrichment, and personal finance management that can be used to develop standalone services or be integrated into existing banking applications. Its partners include ABN AMRO, BNP Paribas Fortis, Nordea, Klarna, and SEB. Tink was founded in 2012 and is based in Stockholm, Sweden.

Fast Travel Games is a game development studio based in Stockholm, Sweden, specializing in virtual reality (VR) games. Founded by industry veterans with experience at renowned studios, the company aims to transform gaming experiences by leveraging the immersive potential of VR technology. Fast Travel Games focuses on creating rich narratives and interactive environments that allow players to explore their surroundings and collaborate with others. The studio emphasizes social gameplay and storytelling elements, catering to the growing demand for engaging and dynamic gaming experiences in the virtual space.

Traplight creates ultra approachable and deep F2P games. From the first seconds their games offer you fun, effortless gameplay and a deep, empowering progression. They focus on creating entertainment that lasts for years and is always fresh. Players are the ones they create their games for, not us. This drives us to make fun, empowering and coherent gaming experiences that their players truly want. Founded in 2010 and based in Tampere, Finland, Traplight currently has a 28 strong team working on several games. Traplight’s team and vision have been backed up by renowned game investors such as Initial Capital, Korea Investment Partners, Sunstone Capital and Finnvera Venture Capital. Traplight’s Big Bang Racing was chosen as Best of 2016 in AppStore, and currently the company is preparing to soft launch their next big hit soon.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

OxThera AB is a biopharmaceutical company focused on developing innovative therapies for the treatment of primary and secondary hyperoxaluria, a condition that can lead to kidney damage. Founded in 2005 and headquartered in Stockholm, Sweden, with an additional facility in Knoxville, Tennessee, OxThera specializes in products that utilize bacteria and enzymes to manage oxalate levels in the body. Its leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced endogenously, and Oxazyme, a non-systemic oral drug made from recombinant oxalate decarboxylase aimed at treating dietary hyperoxaluria and preventing kidney stones. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in addressing unmet medical needs in this therapeutic area. The company holds worldwide patents for its unique compositions and treatment methods targeting hyperoxaluria.

Neo4j, Inc. is a developer of a graph database platform that helps organizations uncover the business value of connections, influences, and relationships within their data. Founded in 2007 and headquartered in San Mateo, California, the company offers a platform that supports various applications, including artificial intelligence, fraud detection, identity management, analytics, and recommendation systems. Neo4j's technology is utilized by a diverse range of industries such as financial services, retail, government, and telecommunications, enabling clients to adapt to changing business needs and scale their analytical workloads effectively. The platform is available both as a fully managed cloud service and as a self-hosted solution, providing flexibility for developers and data scientists to build intelligent applications and machine learning workflows.

Fast Travel Games is a game development studio based in Stockholm, Sweden, specializing in virtual reality (VR) games. Founded by industry veterans with experience at renowned studios, the company aims to transform gaming experiences by leveraging the immersive potential of VR technology. Fast Travel Games focuses on creating rich narratives and interactive environments that allow players to explore their surroundings and collaborate with others. The studio emphasizes social gameplay and storytelling elements, catering to the growing demand for engaging and dynamic gaming experiences in the virtual space.

Tink is a cloud-based open banking platform that provides the infrastructure and value-adding data products that are enabling the future of financial services. Tink offers products such as account aggregation, payment initiation, data enrichment, and personal finance management that can be used to develop standalone services or be integrated into existing banking applications. Its partners include ABN AMRO, BNP Paribas Fortis, Nordea, Klarna, and SEB. Tink was founded in 2012 and is based in Stockholm, Sweden.

Traplight creates ultra approachable and deep F2P games. From the first seconds their games offer you fun, effortless gameplay and a deep, empowering progression. They focus on creating entertainment that lasts for years and is always fresh. Players are the ones they create their games for, not us. This drives us to make fun, empowering and coherent gaming experiences that their players truly want. Founded in 2010 and based in Tampere, Finland, Traplight currently has a 28 strong team working on several games. Traplight’s team and vision have been backed up by renowned game investors such as Initial Capital, Korea Investment Partners, Sunstone Capital and Finnvera Venture Capital. Traplight’s Big Bang Racing was chosen as Best of 2016 in AppStore, and currently the company is preparing to soft launch their next big hit soon.

Templafy ApS specializes in template and document management solutions designed to enhance business document creation across various industries, including banking, finance, consulting, education, insurance, consumer, and legal sectors. Founded in 2013 and headquartered in Copenhagen, Denmark, Templafy offers a platform that integrates seamlessly with existing software to automate document generation, ensuring brand compliance and improving productivity. Its services include dynamic personalization, document automation, content accessibility, and template governance, enabling organizations to create compliant, high-performing documents efficiently. The company supports millions of users globally, serving over 800 enterprise customers, including notable names like KPMG and IKEA. Templafy operates in multiple countries, including the United States, Germany, the Netherlands, the United Kingdom, Singapore, Hong Kong, Australia, New Zealand, and Spain.

Ministry of Games is a mobile game development studio that designs and develops games focused on experience. It aims to bring RPGs to mobile platforms. The company is backed by Initial Capital, Index Ventures, Sunstone Capital, Proxy Ventures, Henric Suuronen, Markus Pasula, and Tekes. Ministry of Games was founded in 2014 and is based in Helsinki, Finland.

Neo4j, Inc. is a developer of a graph database platform that helps organizations uncover the business value of connections, influences, and relationships within their data. Founded in 2007 and headquartered in San Mateo, California, the company offers a platform that supports various applications, including artificial intelligence, fraud detection, identity management, analytics, and recommendation systems. Neo4j's technology is utilized by a diverse range of industries such as financial services, retail, government, and telecommunications, enabling clients to adapt to changing business needs and scale their analytical workloads effectively. The platform is available both as a fully managed cloud service and as a self-hosted solution, providing flexibility for developers and data scientists to build intelligent applications and machine learning workflows.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Traplight creates ultra approachable and deep F2P games. From the first seconds their games offer you fun, effortless gameplay and a deep, empowering progression. They focus on creating entertainment that lasts for years and is always fresh. Players are the ones they create their games for, not us. This drives us to make fun, empowering and coherent gaming experiences that their players truly want. Founded in 2010 and based in Tampere, Finland, Traplight currently has a 28 strong team working on several games. Traplight’s team and vision have been backed up by renowned game investors such as Initial Capital, Korea Investment Partners, Sunstone Capital and Finnvera Venture Capital. Traplight’s Big Bang Racing was chosen as Best of 2016 in AppStore, and currently the company is preparing to soft launch their next big hit soon.

Pulmologix AB is a clinical stage company based in Stockholm, Sweden, that specializes in developing and manufacturing innovative treatments for respiratory diseases, particularly focusing on early onset allergic asthma. Founded in 2006, the company is dedicated to advancing oral non-steroidal anti-asthmatic drugs aimed at improving patient outcomes in asthma management. Through its research and development efforts, Pulmologix seeks to explore new medical approaches that address unmet needs in respiratory care.

Tink is a cloud-based open banking platform that provides the infrastructure and value-adding data products that are enabling the future of financial services. Tink offers products such as account aggregation, payment initiation, data enrichment, and personal finance management that can be used to develop standalone services or be integrated into existing banking applications. Its partners include ABN AMRO, BNP Paribas Fortis, Nordea, Klarna, and SEB. Tink was founded in 2012 and is based in Stockholm, Sweden.

Issuu, Inc. is a digital publishing and discovery platform founded in 2006, with headquarters in Palo Alto, California, and additional offices in Berlin and Copenhagen. The company offers a comprehensive suite of tools for digital publishing, allowing users to create and share a variety of content, including magazines, newspapers, catalogs, and portfolios. With a focus on enhancing the reader experience, Issuu supports over 17 million publications and serves more than 80 million active readers each month. The platform enables publishers, both large and small, to easily upload and distribute their work while maintaining the visual appeal associated with print media. Moreover, Issuu provides various features, such as custom viewer themes, API integrations, and monetization solutions, which facilitate seamless publication management and audience engagement across devices and social networks.

Templafy ApS specializes in template and document management solutions designed to enhance business document creation across various industries, including banking, finance, consulting, education, insurance, consumer, and legal sectors. Founded in 2013 and headquartered in Copenhagen, Denmark, Templafy offers a platform that integrates seamlessly with existing software to automate document generation, ensuring brand compliance and improving productivity. Its services include dynamic personalization, document automation, content accessibility, and template governance, enabling organizations to create compliant, high-performing documents efficiently. The company supports millions of users globally, serving over 800 enterprise customers, including notable names like KPMG and IKEA. Templafy operates in multiple countries, including the United States, Germany, the Netherlands, the United Kingdom, Singapore, Hong Kong, Australia, New Zealand, and Spain.

FBC Device ApS, founded in 2005 and based in Risskov, Denmark, specializes in the manufacture and marketing of spinal fusion implants. The company achieved its first significant milestone in 2013 when its Statur product line received the CE mark, allowing it to enter the European and Canadian markets. FBC Device has also obtained ISO 13485 certification, reflecting its commitment to high-quality standards. Its innovative two-piece anterior interbody fusion implant incorporates tantalum spheres as radiologic markers, enabling surgeons to adjust lordosis during procedures. This technology aims to improve patient outcomes by offering a self-adapting ALIF cage that positively influences sagittal balance. The company holds patents in Europe and the United States, further solidifying its position in the spinal implant industry.

Mofibo, founded in Copenhagen in 2013, is one of the pioneering book subscription services globally. The company provides e-books through a proprietary platform that operates on a monthly subscription model, allowing consumers to access a diverse range of titles. Currently active in three countries, Mofibo plans to expand its reach into additional markets within the next year. With a focus on transforming the reading experience, Mofibo employs a data-driven and customer-centric approach to enhance how millions of people interact with books.

Neo4j, Inc. is a developer of a graph database platform that helps organizations uncover the business value of connections, influences, and relationships within their data. Founded in 2007 and headquartered in San Mateo, California, the company offers a platform that supports various applications, including artificial intelligence, fraud detection, identity management, analytics, and recommendation systems. Neo4j's technology is utilized by a diverse range of industries such as financial services, retail, government, and telecommunications, enabling clients to adapt to changing business needs and scale their analytical workloads effectively. The platform is available both as a fully managed cloud service and as a self-hosted solution, providing flexibility for developers and data scientists to build intelligent applications and machine learning workflows.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company based in Denmark, specializing in the discovery and development of RNA-targeted therapies. Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, the company focuses on delivering potent single-stranded LNA-based drug candidates for various disease states. Santaris Pharma's research and development efforts primarily target infectious diseases and cardiometabolic disorders, while also engaging in partnerships with major pharmaceutical companies to address a broader range of therapeutic areas, including cancer, cardiovascular disease, and rare genetic disorders. Founded in 2003, the company holds exclusive worldwide rights for the manufacture and sale of products containing LNA as an active ingredient, supporting its goal of obtaining marketing approval for its innovative therapies.

Nuevolution is a prominent small molecule lead discovery company established in 2001 and headquartered in Copenhagen, Denmark. The firm specializes in developing innovative treatments for human diseases, particularly in oncology and inflammatory conditions. Central to its operations is Chemetics®, a proprietary drug discovery platform that combines wet chemistry with molecular biology, allowing for the rapid synthesis and DNA-tagging of millions of diverse small molecule compounds. This advanced technology enables efficient screening to identify potent drug leads at an unprecedented scale and speed. With a library exceeding 1 billion compounds, Nuevolution collaborates with various pharmaceutical and biotechnology companies, including notable partnerships with leading industry names. Additionally, the company is involved in a joint venture focused on the discovery and development of small molecule drugs targeting epigenetic factors. Nuevolution's capabilities have led to the identification of novel ligands with potential applications in addressing significant unmet medical needs across various therapeutic areas. The company is privately owned by a group of key Scandinavian investors.

Neo4j, Inc. is a developer of a graph database platform that helps organizations uncover the business value of connections, influences, and relationships within their data. Founded in 2007 and headquartered in San Mateo, California, the company offers a platform that supports various applications, including artificial intelligence, fraud detection, identity management, analytics, and recommendation systems. Neo4j's technology is utilized by a diverse range of industries such as financial services, retail, government, and telecommunications, enabling clients to adapt to changing business needs and scale their analytical workloads effectively. The platform is available both as a fully managed cloud service and as a self-hosted solution, providing flexibility for developers and data scientists to build intelligent applications and machine learning workflows.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Podio, a collaborative work platform now part of Citrix, is designed to enhance how teams manage their daily tasks and workflows. It empowers users to create customized workspaces that can be accessed in real-time by team members, integrating various functionalities such as messaging, task management, reporting, and contact management. By offering a wide range of specialized and flexible work applications, Podio streamlines processes and reduces the need for multiple disjointed tools, all while providing a single, organized environment for users. Trusted by thousands of teams and organizations globally, Podio facilitates efficient work processes and connects various work activities within a cohesive platform. Based in Copenhagen, the company has a diverse team comprising employees from Germany, France, Britain, and Denmark, led by CEO Tommy Ahlers.

Acarix A/S is a medical technology company based in Sweden, specializing in the development of innovative solutions for the rapid exclusion of coronary artery disease (CAD). Established in 2009 as a spin-out from Coloplast A/S, Acarix emerged from pioneering research conducted at Aalborg University in Denmark. The company’s flagship product, the CE-marked CADScor System, has also received DeNovo approval from the FDA. This system is designed for patients experiencing chest pain with suspected CAD, utilizing advanced acoustics and artificial intelligence to non-invasively rule out the disease in under 10 minutes, achieving at least 96 percent certainty. By providing a quick and reliable diagnostic alternative, Acarix aims to significantly reduce the number of unnecessary invasive procedures and associated healthcare costs.

Action Pharma A/S is a biotechnology company focused on research and development of innovative drug candidates aimed at treating cardiovascular, inflammatory, and metabolic diseases. Founded in 2000 and based in Holte, Denmark, the company specializes in discovering and developing new treatment concepts, particularly those targeting melanocortin receptors. Its product pipeline includes AP214, a modified peptide analogue for preventing post-surgical kidney injury related to cardiac surgeries, as well as the AP1030 and AP11 series, which are oral anti-diabetic medications designed for patients with type-II diabetes who are overweight or obese. Additionally, Action Pharma is developing AP1189, an oral anti-inflammatory compound for conditions like inflammatory bowel disease and rheumatoid arthritis, and AP405, which targets inflammatory skin diseases such as atopic dermatitis. The company's efforts are geared toward achieving clinical proof of concept for its drug candidates, facilitating partnerships for further development and commercialization.

Neo4j, Inc. is a developer of a graph database platform that helps organizations uncover the business value of connections, influences, and relationships within their data. Founded in 2007 and headquartered in San Mateo, California, the company offers a platform that supports various applications, including artificial intelligence, fraud detection, identity management, analytics, and recommendation systems. Neo4j's technology is utilized by a diverse range of industries such as financial services, retail, government, and telecommunications, enabling clients to adapt to changing business needs and scale their analytical workloads effectively. The platform is available both as a fully managed cloud service and as a self-hosted solution, providing flexibility for developers and data scientists to build intelligent applications and machine learning workflows.

Action Pharma A/S is a biotechnology company focused on research and development of innovative drug candidates aimed at treating cardiovascular, inflammatory, and metabolic diseases. Founded in 2000 and based in Holte, Denmark, the company specializes in discovering and developing new treatment concepts, particularly those targeting melanocortin receptors. Its product pipeline includes AP214, a modified peptide analogue for preventing post-surgical kidney injury related to cardiac surgeries, as well as the AP1030 and AP11 series, which are oral anti-diabetic medications designed for patients with type-II diabetes who are overweight or obese. Additionally, Action Pharma is developing AP1189, an oral anti-inflammatory compound for conditions like inflammatory bowel disease and rheumatoid arthritis, and AP405, which targets inflammatory skin diseases such as atopic dermatitis. The company's efforts are geared toward achieving clinical proof of concept for its drug candidates, facilitating partnerships for further development and commercialization.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company based in Denmark, specializing in the discovery and development of RNA-targeted therapies. Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, the company focuses on delivering potent single-stranded LNA-based drug candidates for various disease states. Santaris Pharma's research and development efforts primarily target infectious diseases and cardiometabolic disorders, while also engaging in partnerships with major pharmaceutical companies to address a broader range of therapeutic areas, including cancer, cardiovascular disease, and rare genetic disorders. Founded in 2003, the company holds exclusive worldwide rights for the manufacture and sale of products containing LNA as an active ingredient, supporting its goal of obtaining marketing approval for its innovative therapies.

Issuu, Inc. is a digital publishing and discovery platform founded in 2006, with headquarters in Palo Alto, California, and additional offices in Berlin and Copenhagen. The company offers a comprehensive suite of tools for digital publishing, allowing users to create and share a variety of content, including magazines, newspapers, catalogs, and portfolios. With a focus on enhancing the reader experience, Issuu supports over 17 million publications and serves more than 80 million active readers each month. The platform enables publishers, both large and small, to easily upload and distribute their work while maintaining the visual appeal associated with print media. Moreover, Issuu provides various features, such as custom viewer themes, API integrations, and monetization solutions, which facilitate seamless publication management and audience engagement across devices and social networks.